PMID- 30071889
OWN - NLM
STAT- MEDLINE
DCOM- 20190107
LR  - 20190107
IS  - 1749-799X (Electronic)
IS  - 1749-799X (Linking)
VI  - 13
IP  - 1
DP  - 2018 Aug 2
TI  - Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a 
      meta-analysis.
PG  - 194
LID - 10.1186/s13018-018-0865-3 [doi]
LID - 194
AB  - BACKGROUND: The standard treatment for osteoporosis was controversial. Denosumab 
      and bisphosphonates were two most common drugs. The purpose of this study was to 
      compare the efficacy and safety of denosumab with bisphosphonates to treat 
      osteoporosis. METHODS: Published literatures, only including randomized 
      controlled trials (RCTs), were searched in the following electronic databases: 
      PubMed, Embase, Web of Science, Cochrane Library, and Google database from 
      inception to April 20 2018. Studies that compared denosumab with bisphosphonates 
      to treat osteoporosis were included. Random-effect model was used for 
      meta-analysis due to the unavoidable clinical heterogeneity. We used the risk of 
      fracture as the primary outcome. Stata 12.0 was used for meta-analysis. RESULTS: 
      Eleven studies involving 5446 patients (denosumab = 2873, bisphosphonates = 2573) 
      were included in the present meta-analysis. There was no significant difference 
      between the risk of fracture (risk ratio (RR), 1.13; 95% confidence interval 
      (CI), 0.82-1.55; P = 0.466), adverse events (AEs) (RR 1.00; 95% CI 0.96-1.04; 
      P = 0.957) and withdrawn due to AEs (RR 0.68; 95% CI 0.34-137; P = 0.280). 
      Denosumab compared with bisphosphonates significantly increased change in total 
      hip, femoral neck, lumbar spine, and one-third radius bone mineral density (BMD) 
      for postmenopausal osteoporosis patients (P < 0.05). CONCLUSIONS: Our 
      meta-analysis suggested that denosumab but not bisphosphonates significantly 
      increased change in total hip, femoral neck, lumbar spine, and one-third radius 
      BMD for postmenopausal osteoporosis patients. Current evidence suggested no 
      benefit of denosumab for reducing risk of fracture than bisphosphonates. More 
      long-term follow-up RCTs are needed to identify the potential complications of 
      denosumab.
FAU - Wu, Jiaqi
AU  - Wu J
AD  - The Second Department of Orthepaedics, Harrison International Peace Hospital, No. 
      180 Renmin East Road, Hengshui, 053000, Hebei, China.
FAU - Zhang, Qingsheng
AU  - Zhang Q
AD  - The Second Department of Orthepaedics, Harrison International Peace Hospital, No. 
      180 Renmin East Road, Hengshui, 053000, Hebei, China.
FAU - Yan, Guanghui
AU  - Yan G
AD  - The Second Department of Orthepaedics, Harrison International Peace Hospital, No. 
      180 Renmin East Road, Hengshui, 053000, Hebei, China.
FAU - Jin, Xianhui
AU  - Jin X
AD  - The Second Department of Orthepaedics, Harrison International Peace Hospital, No. 
      180 Renmin East Road, Hengshui, 053000, Hebei, China. 2593463778@qq.com.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20180802
PL  - England
TA  - J Orthop Surg Res
JT  - Journal of orthopaedic surgery and research
JID - 101265112
RN  - 0 (Bone Density Conservation Agents)
RN  - 0 (Diphosphonates)
RN  - 4EQZ6YO2HI (Denosumab)
SB  - IM
MH  - Bone Density/drug effects
MH  - Bone Density Conservation Agents/*therapeutic use
MH  - Denosumab/*therapeutic use
MH  - Diphosphonates/*therapeutic use
MH  - Humans
MH  - Osteoporosis, Postmenopausal/*drug therapy
MH  - Randomized Controlled Trials as Topic
PMC - PMC6090940
OTO - NOTNLM
OT  - Bisphosphonates
OT  - Denosumab
OT  - Fracture
OT  - Meta-analysis
COIS- This is a meta-analysis; no relative problems exist. Not applicable. The authors 
      declare that they have no competing interests. Springer Nature remains neutral 
      with regard to jurisdictional claims in published maps and institutional 
      affiliations.
EDAT- 2018/08/04 06:00
MHDA- 2019/01/08 06:00
PMCR- 2018/08/02
CRDT- 2018/08/04 06:00
PHST- 2018/04/20 00:00 [received]
PHST- 2018/06/14 00:00 [accepted]
PHST- 2018/08/04 06:00 [entrez]
PHST- 2018/08/04 06:00 [pubmed]
PHST- 2019/01/08 06:00 [medline]
PHST- 2018/08/02 00:00 [pmc-release]
AID - 10.1186/s13018-018-0865-3 [pii]
AID - 865 [pii]
AID - 10.1186/s13018-018-0865-3 [doi]
PST - epublish
SO  - J Orthop Surg Res. 2018 Aug 2;13(1):194. doi: 10.1186/s13018-018-0865-3.